FDA Nixes Innovator Industry-Backed Changes To Citizen Petition Rule
Agency rejects PhRMA requests to ease certification process and limit rule's application; separately, law firm Hyman, Phelps & McNamara objects to FDA practice of delaying ANDA approval announcements until it issues a petition decision.
You may also be interested in...
AstraZeneca's legal gambit results in almost two more weeks of sales for the statin even though the court ultimately agreed with FDA on labeling carve-out for orphan indication.
Company is waging the same legal battle Otsuka lost last year, arguing pediatric orphan indication should block approvals of ANDAs.
FDA's decision that Hi-Tech forfeited its generic exclusivity for Merck's ophthalmic Cosopt (dorzolamide/timolol) means that firms may need to give more weight to the strength of their patent challenges as they make filing decisions in the future